Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (141-150 of 182) with videos related to

Pageof 19
Sort By:
The New England Journal of Medicine|November 13, 2018
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaDeepak L Bhatt, P Gabriel Steg, Michael Miller, et al.
European Heart Journal|January 22, 2024
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trialNeila Sayah, Deepak L Bhatt, Michael Miller, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|April 7, 2016
Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA)Harold Bays, Shanu N Kothari, Dan E Azagury, et al.
Journal of Clinical Lipidology|February 20, 2016
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARYHarold E Bays, Peter H Jones, Terry A Jacobson, et al.
Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.
Journal of Clinical Lipidology|February 20, 2016
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORTHarold E Bays, Peter H Jones, Terry A Jacobson, et al.
Journal of Clinical Lipidology|March 21, 2020
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Journal of Cardiovascular Computed Tomography|January 2, 2026
Distribution of coronary artery calcium volume and density by age, sex, and race using AI-based quantification algorithmGabrielle Gershon, Kari Zhou, Yan Yang, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Pageof 19

Showing results (141-150 of 182) with videos related to

Sort By:
Pageof 19
The New England Journal of Medicine|November 13, 2018
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaDeepak L Bhatt, P Gabriel Steg, Michael Miller, et al.
European Heart Journal|January 22, 2024
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trialNeila Sayah, Deepak L Bhatt, Michael Miller, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|April 7, 2016
Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA)Harold Bays, Shanu N Kothari, Dan E Azagury, et al.
Journal of Clinical Lipidology|February 20, 2016
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARYHarold E Bays, Peter H Jones, Terry A Jacobson, et al.
Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.
Journal of Clinical Lipidology|February 20, 2016
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORTHarold E Bays, Peter H Jones, Terry A Jacobson, et al.
Journal of Clinical Lipidology|March 21, 2020
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Journal of Cardiovascular Computed Tomography|January 2, 2026
Distribution of coronary artery calcium volume and density by age, sex, and race using AI-based quantification algorithmGabrielle Gershon, Kari Zhou, Yan Yang, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Pageof 19